Results 271 to 280 of about 768,066 (299)
Some of the next articles are maybe not open access.
Nihon rinsho. Japanese journal of clinical medicine, 2016
Since 2011, several effective drugs for patients with metastatic melanoma, including the BRAF inhibitors, the MEK inhibitors and the immune checkpoint inhibitors, have been ap- proved. Ipilimumab, nivolumab and the combination have shown response rates of 10-20%, 20-40% and up to 60% and a median progression-free survival of 2, 7 and 12 months, respec-
openaire +2 more sources
Since 2011, several effective drugs for patients with metastatic melanoma, including the BRAF inhibitors, the MEK inhibitors and the immune checkpoint inhibitors, have been ap- proved. Ipilimumab, nivolumab and the combination have shown response rates of 10-20%, 20-40% and up to 60% and a median progression-free survival of 2, 7 and 12 months, respec-
openaire +2 more sources
Pathology, 2016
Cutaneous melanoma occurs only rarely in children under 10 years of age. Mimics of melanoma, including Spitz naevi and proliferative nodules in congenital melanocytic naevi are much more frequent in this age group. Melanoma arising in congenital melanocytic naevus is uncommon, but can show aggressive behaviour.
openaire +2 more sources
Cutaneous melanoma occurs only rarely in children under 10 years of age. Mimics of melanoma, including Spitz naevi and proliferative nodules in congenital melanocytic naevi are much more frequent in this age group. Melanoma arising in congenital melanocytic naevus is uncommon, but can show aggressive behaviour.
openaire +2 more sources
Recent developments in the medical and surgical treatment of melanoma
Ca-A Cancer Journal for Clinicians, 2014Jonathan S Zager
exaly
An Evidence-based Staging System for Cutaneous Melanoma
Ca-A Cancer Journal for Clinicians, 2004Michael B Atkins +2 more
exaly